A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.
about
Genetic prediction of future type 2 diabetesA comprehensive review of genetic association studiesAn oxidized lipid-peroxisome proliferator-activated receptor gamma-chemokine pathway in the regulation of macrophage-vascular smooth muscle cell adhesionDeletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistancePhysiologic characterization of type 2 diabetes-related lociGenes, diet and type 2 diabetes mellitus: a reviewA haplotype map of the human genomeImplication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population.Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight.Prevalence, predisposition and prevention of type II diabetes.Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?Genetics of Insulin Resistance and the Metabolic SyndromeRecent advances in the molecular genetics of type 2 diabetes mellitusGenetics of oxidative stress in obesityThe Convergence of Systems and Reductionist Approaches in Complex Trait AnalysisT2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic StudiesInhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetesCMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivoDependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivationHuman-specific SNP in obesity genes, adrenergic receptor beta2 (ADRB2), Beta3 (ADRB3), and PPAR γ2 (PPARG), during primate evolutionA genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variantsGenetic mapping in human diseaseHuman genetics as a model for target validation: finding new therapies for diabetes.Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?Exercise training, genetics and type 2 diabetes-related phenotypes.The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.Systems genetics of metabolism: the use of the BXD murine reference panel for multiscalar integration of traitsIndividualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Ppargamma2 is a key driver of longevity in the mouse.Overcoming the winner's curse: estimating penetrance parameters from case-control data.Association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma gene and strength athlete status.The association between the Pro12Ala variant in the PPARγ2 gene and type 2 diabetes mellitus and obesity in a Chinese populationAn Asp7Gly substitution in PPARG is associated with decreased transcriptional activation activity.Positive selection within the Schizophrenia-associated GABA(A) receptor beta(2) geneThe genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies.Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant riskBirth weight and blood lipid levels in Spanish adolescents: influence of selected APOE, APOC3 and PPARgamma2 gene polymorphisms. The AVENA Study.PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes.
P2860
Q21563435-002D83C1-F5FD-47C9-A43F-9446474B4AB4Q22337119-EEF13F37-FCB4-4B0E-8141-E8841266CB57Q24300694-96C5D552-EC58-4B6F-BDFB-86F871D1CD4AQ24555727-C9B7C813-651E-44C4-8F95-F4D30A7F1621Q24630735-CA9FA1A1-1DE0-49DC-85EB-01F85274CFD6Q24672249-19C1F427-5301-4A66-9DE2-E020572B6E40Q24679827-D14DAA5B-F7F5-4B08-9D33-EAB73FF33E1FQ24791420-A9CF6765-89F6-4044-B29E-42023496637AQ24799062-8317CA9C-A336-4E0F-A45D-5660CAD28A50Q24815863-FDF69A59-C271-492B-A398-6620A49556EFQ26739984-F3FA169A-EB97-477E-BE85-F94AEEFA26FCQ26745624-61F0D7D1-430D-43C8-A365-5223393A969FQ26996335-6CEBEF91-9226-499B-BBD9-C8DD99AEE3D1Q27001710-662C1276-87C5-490E-B74A-8B93AA374A51Q27025585-EFD9F332-BABE-4112-A160-B17F2A7726D0Q27649827-2A908072-9FD6-43A2-893F-2542037B0D41Q28221639-4FC5FA3F-6CC0-4348-BAAD-87952504274FQ28360697-7945B813-78FD-42F8-8B26-72A0C53C3AA9Q28540538-4D735224-A8D4-4356-B218-BF29E67DD4A1Q28580795-D33B2324-D0D2-4AE7-9729-3403A1B1CEA5Q28728262-F6A67CC7-FD3C-401F-8A4C-2349908F660BQ29547210-884B0236-EDF8-4249-B7F7-1A77407D1550Q29614943-A68CD38A-C00E-45A0-A7EB-37C5D90528E6Q30234640-3C3D8096-4BE0-4BF3-A1F1-031A58C68942Q30388214-AD1EA20D-76A7-4C2D-AC5A-7AE64AB5EBBBQ30417635-C2A3FF64-0DD1-4FD2-8EED-D35301A83569Q30482667-9AA4B164-C2D7-4ECC-8363-A339CEF69B62Q30485668-E59E2F60-B21E-4DA1-BDC0-6FA84C3D68B4Q30571118-58B5F098-74F8-42FC-8B27-4D5DBF173321Q30597265-B96BBD0B-AFE5-4B7F-A732-C712A3937D14Q30975227-2BCEBAF6-6C4A-4534-B9DB-DF1F63C28472Q31105516-9281C81E-4F0D-4251-843F-F5C2D7D99CBBQ31121358-8F7FC025-3541-418F-B028-E542AEC80802Q31132059-0F07685B-CDDE-4799-94C8-CAF7D9B7C7B6Q31148902-2781589A-5E60-4AA0-B6FE-688E5A099B6EQ33285476-B603BAC3-2D90-4CC7-B0E7-8A9F36FEB5DEQ33337217-3C850780-7B92-4430-83AB-304CA6FA46A5Q33348834-17F1A614-8675-4E02-9738-382D43FCD974Q33383632-BC1B8E29-7579-43B3-8CE7-4545A17B8937Q33461994-231585E3-8BEC-4CD3-B777-984C352440BA
P2860
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
A Pro12Ala substitution in PPA ...... improved insulin sensitivity.
@en
type
label
A Pro12Ala substitution in PPA ...... improved insulin sensitivity.
@en
prefLabel
A Pro12Ala substitution in PPA ...... improved insulin sensitivity.
@en
P2093
P356
P1433
P1476
A Pro12Ala substitution in PPA ...... improved insulin sensitivity.
@en
P2093
Fujimoto W
Kuusisto J
Mykkänen L
Pihlajamäki J
P2888
P304
P356
10.1038/3099
P407
P577
1998-11-01T00:00:00Z